Evidence map›Paper›PMID 38496630›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Corticosteroids for infectious critical illness: A multicenter target trial emulation stratified by predicted organ dysfunction trajectory.

Suraj Rajendran, Zhenxing Xu, Weishen Pan, Chengxi Zang, Ilias Siempos, Lisa Torres, Jie Xu, Jiang Bian, Edward J Schenck, Fei Wang

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Suraj RajendranTri-Institutional Computational Biology & Medicine Program, Cornell University, NY, USA.ORCID 0000-0002-8149-0157
Zhenxing XuDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-9515-523X
Weishen PanDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Chengxi ZangDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Ilias SiemposDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
Lisa TorresDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
Jie XuDepartment of Health Outcomes and Biomedical Informatics. College of Medicine. University of Florida. Gainesville, FL, USA.
Jiang BianDepartment of Health Outcomes and Biomedical Informatics. College of Medicine. University of Florida. Gainesville, FL, USA.ORCID 0000-0002-2238-5429
Edward J SchenckDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
Fei WangDivision of Health Informatics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Cornell University · USNewYork–Presbyterian Hospital · USUniversity of Florida · US

Funding

TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s DiseaseR01AG076448 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Li Gan · 2022 to 2026
$4.0M
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical KnowledgeR01AG076234 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2022 to 2026
$3.8M
Developing Suicide Risk Algorithms for Diverse Clinical Settings using Data FusionR01MH124740 · NIMH · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ASELTINE, ROBERT H, CHEN, KUN · 2020 to 2023
$3.2M
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AIR01AG080991 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2023 to 2026
$3.1M
Disparities of Alzheimer's disease progression in Sexual Minority IndividualsR01AG080624 · NIA · UNIVERSITY OF FLORIDA · PI Jiang Bian, Yi Guo · 2023 to 2026
$3.1M
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior MarkersRF1AG072449 · NIA · MICHIGAN STATE UNIVERSITY · PI DODGE, HIROKO HAYAMA, WANG, FEI · 2021 to 2023
$2.6M
Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of HealthRF1AG084178 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BIAN, JIANG, HU, HUI · 2023 to 2023
$2.6M
Necroinflammatory Cell Death in SepsisK23HL151876 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHENCK, EDWARD JAMES · 2021 to 2025
$975k
Cellular and Metabolic Dysfunction in Sepsis-Induced Immune ParalysisK23GM151730 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TORRES, LISA KRISTINA · 2023 to 2025
$588k
NHLBI NIH HHS K23 HL151876NIA NIH HHS R01 AG076234NIA NIH HHS R01 AG076448NIA NIH HHS R01 AG080624NIA NIH HHS R01 AG080991NIA NIH HHS RF1 AG072449NIA NIH HHS RF1 AG084178NIGMS NIH HHS K23 GM151730NIMH NIH HHS R01 MH124740
6 · The paper itself

Abstract

Corticosteroids decrease the duration of organ dysfunction in a range of infectious critical illnesses, but their risk and benefit are not fully defined using this construct. This retrospective multicenter study aimed to evaluate the association between usage of corticosteroids and mortality of patients with infectious critical illness by emulating a target trial framework. The study employed a novel stratification method with predictive machine learning (ML) subphenotyping based on organ dysfunction trajectory. Our analysis revealed that corticosteroids' effectiveness varied depending on the stratification method. The ML-based approach identified four distinct subphenotypes, two of which had a large enough sample size in our patient cohorts for further evaluation: "Rapidly Improving" (RI) and "Rapidly Worsening," (RW) which showed divergent responses to corticosteroid treatment. Specifically, the RW group either benefited or were not harmed from corticosteroids, whereas the RI group appeared to derive harm. In the development cohort, which comprised of a combination of patients from the eICU and MIMIC-IV datasets, hazard ratio estimates for the primary outcome, 28-day mortality, in the RW group was 1.05 (95% CI: 0.96 - 1.04) whereas for the RW group, it was 1.40 (95% CI: 1.28 - 1.54). For the validation cohort, which comprised of patients from the Critical carE Database for Advanced Research, estimates for 28-day mortality for the RW and RI groups were 1.24 (95% CI: 1.05 - 1.46) and 1.34 (95% CI: 1.14 - 1.59), respectively. For secondary outcomes, the RW group had a shorter time to ICU discharge and time to cessation of mechanical ventilation with corticosteroid treatment, where the RI group again demonstrated harm. The findings support matching treatment strategies to empirically observed pathobiology and offer a more nuanced understanding of corticosteroid utility. Our results have implications for the design and interpretation of both observational studies and randomized controlled trials (RCTs), suggesting the need for stratification methods that account for the differential response to standard of care.

Identifiers

PMID38496630
PMCPMC10942524
OpenAlexW4392577484

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.